KZR Kezar Life Sciences Inc

Price (delayed)

$0.6507

Market cap

$47.37M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.4

Enterprise value

$32.63M

Based in South San Francisco, Kezar Life Sciences is combining courage, conviction and cutting-edge science to develop breakthrough treatments for immune-mediated and oncologic disorders. The company is pioneering first-in-class, small-molecule ...

Highlights
The debt has contracted by 12% YoY and by 3.4% from the previous quarter
The quick ratio fell by 41% YoY
The net income has contracted by 36% YoY

Key stats

What are the main financial stats of KZR
Market
Shares outstanding
72.8M
Market cap
$47.37M
Enterprise value
$32.63M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.28
Price to sales (P/S)
6.77
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.66
Earnings
Revenue
$7M
EBIT
-$99.75M
EBITDA
-$98.68M
Free cash flow
-$85.16M
Per share
EPS
-$1.4
Free cash flow per share
-$1.17
Book value per share
$2.32
Revenue per share
$0.1
TBVPS
$2.74
Balance sheet
Total assets
$199.13M
Total liabilities
$30.01M
Debt
$18.29M
Equity
$169.12M
Working capital
$169.45M
Liquidity
Debt to equity
0.11
Current ratio
11.49
Quick ratio
11.13
Net debt/EBITDA
0.15
Margins
EBITDA margin
-1,409.7%
Gross margin
100%
Net margin
-1,447.6%
Operating margin
-1,580.2%
Efficiency
Return on assets
-43.4%
Return on equity
-50.4%
Return on invested capital
-48.5%
Return on capital employed
-54.5%
Return on sales
-1,425%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

KZR stock price

How has the Kezar Life Sciences stock price performed over time
Intraday
-1.41%
1 week
1.67%
1 month
-1.41%
1 year
-70.69%
YTD
-31.32%
QTD
8.45%

Financial performance

How have Kezar Life Sciences's revenue and profit performed over time
Revenue
$7M
Gross profit
$7M
Operating income
-$110.61M
Net income
-$101.33M
Gross margin
100%
Net margin
-1,447.6%
The company's operating income fell by 39% YoY
The net income has contracted by 36% YoY

Growth

What is Kezar Life Sciences's growth rate over time

Valuation

What is Kezar Life Sciences stock price valuation
P/E
N/A
P/B
0.28
P/S
6.77
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.66
The EPS has declined by 32% year-on-year
The price to book (P/B) is 84% less than the 5-year quarterly average of 1.7 and 44% less than the last 4 quarters average of 0.5
KZR's equity is down by 33% year-on-year and by 10% since the previous quarter

Efficiency

How efficient is Kezar Life Sciences business performance
KZR's ROE has shrunk by 87% YoY and by 10% QoQ
The return on assets has dropped by 76% year-on-year and by 9% since the previous quarter
The company's return on invested capital has shrunk by 64% YoY and by 10% QoQ

Dividends

What is KZR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for KZR.

Financial health

How did Kezar Life Sciences financials performed over time
KZR's current ratio is down by 41% year-on-year
The quick ratio fell by 41% YoY
The debt is 89% less than the equity
KZR's debt to equity is up by 38% year-on-year and by 10% since the previous quarter
KZR's equity is down by 33% year-on-year and by 10% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.